Graham Makes a Statistically Significant Move in Pharma Services with Latest Platform

Forms Quantive Intelligence through Merger of Biometrics Service Providers

Graham Partners (“Graham”), a private investment firm targeting advanced manufacturing and technology-enabled services businesses, is pleased to announce the formation of Quantive Intelligence (“QI”) through the acquisitions of TechData Service Company, LLC (“TechData”), LLX Solutions, LLC (“LLX”), and R Square Technology, Inc. (“R Square”) (together, the “Legacy Entities”). Collectively, the founder-led Legacy Entities have over 40 years of operating history servicing 14 of the top 20 large pharma sponsors by R&D spend and leading biotech organizations on some of their most innovative therapeutics. Together, these Legacy Entities form a global organization of over 700 employees defined by an exemplary focus on improving patient lives through scientific inquiry and execution.

Headquartered in King of Prussia, Pennsylvania, with additional presence in Massachusetts, Greater China, and a newly formed operation in India, QI is being formed to create a purpose-built decision sciences platform that transforms complex clinical data into confident, regulatory-ready decisions. The Legacy Entities each provide specialized expertise in biostatistics and statistical programming that pharmaceutical and biotechnology organizations rely on to accelerate regulatory approvals and bring new therapies to market. The platform brings together premier organizations that are highly reputable in their respective areas of expertise, backed by experienced founders with decades-long reputations for excellence and quality in the CRO space. QI will be led by seasoned pharma services executive and Graham industry advisor, Samir Shah, as the CEO. Joining Samir on the leadership team are the founder of TechData, Ju Zhang, and the co-founders of LLX, Liang Li and Frank Xin, who will serve as business unit Presidents. Veteran business leader, George Gowen, will serve as CFO & CAO, and Glenn Sward will serve as VP of Talent Acquisition. Samir Shah, CEO of QI, said, “The launch of the Quantive Intelligence platform marks a pivotal moment for the industry, and we believe that this partnership will allow us to unlock more value for our sponsors through providing tailored, bespoke solutions in a rapidly evolving clinical development environment.”*

Graham believes the decision sciences niche presents near-term opportunities for disruptive innovation, as regulatory expectations, increased data volumes, and real-time clinical trials have created a demand for validation frameworks that do not exist today. QI marks the continuation of Graham’s 15+ years of experience investing in medical devices and life sciences, where past and current portfolio companies work in regulated environments, building end-to-end processes across the value chain to bring medical products and / or drugs to market, and innovating to increase productivity and efficiency. Graham has actively pursued an investment in pharma services, specifically submission-stage clinical development services, and believes that QI is well aligned within its broader life sciences thesis.

Graham views QI as a unified platform for the build-out of additional capabilities under the decision sciences umbrella and intends to accelerate growth during its ownership by investing in AI tools and platforms, expanding R programming services, and professionalizing the business by developing commercial and recruiting functions and modernizing its systems and technologies. Josh Wilson, Managing Partner and Chief Operating Officer at Graham Partners, said “QI brings together founder-built businesses with deeply loyal customers and exceptional talent that share a common focus on delivering critical biometrics expertise. We’re excited to leverage our life sciences experience and bench of resources as we aim to build QI into a leading provider in the space.”

About Quantive Intelligence

Quantive Intelligence is a decision sciences platform providing specialized biometrics expertise across biostatistics, statistical programming, and data management functions, supporting clinical development processes for pharmaceutical and biotechnology sponsors. QI operates as the intelligence layer between complex data and confident submissions, helping transform clinical trial data into clear, actionable insights that support regulatory approvals. Headquartered in King of Prussia, Pennsylvania, with additional presence in Waltham, Massachusetts, Greater China, and India, QI serves a diversified base of pharmaceutical and biotechnology customers globally.

Robert W. Baird & Co. served as the exclusive financial advisor to Graham Partners for all transactions.

Synergy Advisors served as the exclusive sell-side advisor to LLX Solutions.

FOR FURTHER INFORMATION CONTACT:  

Josh Wilson (jwilson@grahampartners.net)

Josh Pompan (jpompan@grahampartners.net)

Christina Morin (cmorin@grahampartners.net)

Tel: (610) 408-0500
www.grahampartners.net
Graham Partners on Video

*Graham Partners did not provide direct compensation in exchange for the above statements. However, certain material conflicts of interest are present with respect to Samir Shah’s statements regarding this transaction as a result of his business relationship with Graham Partners and the financial incentives derived therefrom. Legal Disclaimer This press release is for informational purposes and is not an offer to sell, or a solicitation of an offer to buy, securities in the United States or elsewhere. Graham Partners is not utilizing this release to provide investment or other advice, and no information disclosed therein is to be relied upon for the purpose of making investment decisions. Past performance does not guarantee future results and any transactions described are included as representative transactions and are not necessarily reflective of overall performance. It should not be assumed that any investment described herein was or will be profitable. There can be no assurance that historical trends will continue. Graham Partners’ market characterization is based on subjective determinations that it believes reasonable but others may disagree with such characterization. There is no guarantee that Graham Partners’ initiatives will drive value for its investments or accelerate growth or lead Graham Partners’ investments to become profitable.